Due to the rarity and outstanding curative effects of C. sinensis, some natural substitutes such as C. militaris, C. liangshanensis, C. gunnii, and C. cicadicola have been sold in markets (Yang et al. 2009). In addition, several cultured mycelia of C. sinensis and C. militaris fungi have become the main substitutes of the natural species as commercial products, and 50 medicines and two dietary supplements related to cultured Cordyceps have been approved by the State Food and Drug Administration of China since 2002 (Feng, Yang, and Li 2008). For example, JinShuiBao capsule, the commercial product of Cs-4 (Paecilomyces hepialid, a standardized mycelium of C. sinensis), has been used in clinics throughout China. This product generates several million U.S. dollars every year. Synnematum sinensis, Cephalosporium sinensis, Gliocladium roseum, and Mortierella hepialid, the fungus strains isolated from natural C. sinensis, have also been subjected to large- scale fermentation and are used as commercial products (Cheung, Li, and Tsim 2005). Therefore, much effort has been invested in studying the evaluation of the quality, pharmacological activities, and clinical efficacies of natural and cultured cordyceps. In this chapter, we focus on the bioactivities, action mechanisms, and active ingredients of cordyceps, both natural and cultured.
Copyright © 2011 by Taylor and Francis Group, LLC.